Presented at the 3rd Annual Academic Surgical Congress, February 13, 2008, Huntington Beach, CA.
Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: A population-based perspective†
Article first published online: 19 NOV 2008
Copyright © 2008 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 99, Issue 2, pages 87–92, 1 February 2009
How to Cite
Nathan, H., Wolfgang, C. L., Edil, B. H., Choti, M. A., Herman, J. M., Schulick, R. D., Cameron, J. L. and Pawlik, T. M. (2009), Peri-operative mortality and long-term survival after total pancreatectomy for pancreatic adenocarcinoma: A population-based perspective. J. Surg. Oncol., 99: 87–92. doi: 10.1002/jso.21189
- Issue published online: 20 JAN 2009
- Article first published online: 19 NOV 2008
- Manuscript Accepted: 30 SEP 2008
- Manuscript Received: 23 JUL 2008
- total pancreatectomy;
- pancreatic adenocarcinoma;
Background and Objectives
Many surgeons perceive total pancreatectomy (TP) for pancreatic adenocarcinoma to be associated with inferior outcomes compared to partial pancreatectomy (PP), such as pancreaticoduodenectomy (PD) and distal pancreatectomy (DP). We sought to analyze peri-operative mortality and long-term survival following TP versus PP for pancreatic adenocarcinoma.
The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients with resected pancreatic adenocarcinoma (1998–2004). Survival after TP versus PP was compared by tumor location.
Of 3280 patients with resected pancreatic head tumors, 292 underwent TP, and 2988 PD. One-month mortality was 9.0% for TP and 6.5% for PD (P = 0.11). Of 315 patients with resected body/tail tumors, 32 underwent TP, and 283 DP. One-month mortality was 9.3% for TP and 3.9% for DP (P = 0.17). Of 426 patients with resected tumors in unspecified pancreatic locations, 52 underwent TP, and 374 PP. One-month mortality was 5.8% for TP and 6.5% for PP (P = 0.87). Survival analyses demonstrated no difference between TP and PP (hazard ratio (HR) 1.06, P = 0.49 for head; HR 0.84, P = 0.51 for body/tail; HR 1.06, P = 0.79 for unspecified locations).
Peri-operative mortality and long-term survival are similar following TP versus PP for pancreatic adenocarcinoma, supporting the use of TP when oncologically appropriate. J. Surg. Oncol. 2009;99: 87–92. © 2008 Wiley-Liss, Inc.